<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32077471</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1554-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>l-Serine Reduces Spinal Cord Pathology in a Vervet Model of Preclinical ALS/MND.</ArticleTitle><Pagination><StartPage>393</StartPage><EndPage>406</EndPage><MedlinePgn>393-406</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jnen/nlaa002</ELocationID><Abstract><AbstractText>The early neuropathological features of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) are protein aggregates in motor neurons and microglial activation. Similar pathology characterizes Guamanian ALS/Parkinsonism dementia complex, which may be triggered by the cyanotoxin &#x3b2;-N-methylamino-l-alanine (BMAA). We report here the occurrence of ALS/MND-type pathological changes in vervets (Chlorocebus sabaeus; n&#x2009;=&#x2009;8) fed oral doses of a dry powder of BMAA HCl salt (210&#x2009;mg/kg/day) for 140&#x2009;days. Spinal cords and brains from toxin-exposed vervets were compared to controls fed rice flour (210&#x2009;mg/kg/day) and to vervets coadministered equal amounts of BMAA and l-serine (210&#x2009;mg/kg/day). Immunohistochemistry and quantitative image analysis were used to examine markers of ALS/MND and glial activation. UHPLC-MS/MS was used to confirm BMAA exposures in dosed vervets. Motor neuron degeneration was demonstrated in BMAA-dosed vervets by TDP-43+ proteinopathy in anterior horn cells, by reactive astrogliosis, by activated microglia, and by damage to myelinated axons in the lateral corticospinal tracts. Vervets dosed with BMAA + l-serine displayed reduced neuropathological changes. This study demonstrates that chronic dietary exposure to BMAA causes ALS/MND-type pathological changes in the vervet and coadministration of l-serine reduces the amount of reactive gliosis and the number of protein inclusions in motor neurons.</AbstractText><CopyrightInformation>&#xa9; 2020 American Association of Neuropathologists, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Paul Alan</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Chemistry Labs, Jackson Hole, Wyoming.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banack</LastName><ForeName>Sandra Anne</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Chemistry Labs, Jackson Hole, Wyoming.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lecusay</LastName><ForeName>Patricia D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Garamszegi</LastName><ForeName>Susanna P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Hagan</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>James T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Brain Chemistry Labs, Jackson Hole, Wyoming.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metcalf</LastName><ForeName>James S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Brain Chemistry Labs, Jackson Hole, Wyoming.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmour</LastName><ForeName>Roberta M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Behavioural Science Foundation, St. Kitts and Nevis, West Indies.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beierschmitt</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Behavioural Science Foundation, St. Kitts and Nevis, West Indies.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, Ross University School of Veterinary Medicine, St. Kitts and Nevis, West Indies.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>Walter G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mash</LastName><ForeName>Deborah C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, Florida.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000599">Amino Acids, Diamino</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087522">Cyanobacteria Toxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>108SA6URTV</RegistryNumber><NameOfSubstance UI="C001824">beta-N-methylamino-L-alanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000599" MajorTopicYN="N">Amino Acids, Diamino</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087522" MajorTopicYN="N">Cyanobacteria Toxins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011712" MajorTopicYN="N">Pyramidal Tracts</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS/MND</Keyword><Keyword MajorTopicYN="N">BMAA</Keyword><Keyword MajorTopicYN="N">Cyanobacteria</Keyword><Keyword MajorTopicYN="N">Guam ALS/PDC</Keyword><Keyword MajorTopicYN="N">Motor neurons</Keyword><Keyword MajorTopicYN="N">Neurofibrillary tangles</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32077471</ArticleId><ArticleId IdType="pmc">PMC7092359</ArticleId><ArticleId IdType="doi">10.1093/jnen/nlaa002</ArticleId><ArticleId IdType="pii">5740037</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Calvo A, Moglia C, Lunetta C, et al. Factors predicting survival in ALS: A multicenter Italian study. J Neurol 2017;264:54&#x2013;63</Citation><ArticleIdList><ArticleId IdType="pubmed">27778156</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, van den Berg LH, Veldink J.. Gene discovery in amyotrophic lateral sclerosis: Implications for clinical management. Nat Rev Neurol 2017;13:96&#x2013;104</Citation><ArticleIdList><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Schulte DJ, et al. Neuropathology of amyotrophic lateral sclerosis and its variants. Neurol Clin 2015;33:855&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon MS, Wosiski-Kuhn M, Gillespie R, et al. Inflammation, immunity, and amyotrophic lateral sclerosis: I. Etiology and pathology. Muscle Nerve 2019;59:10&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pubmed">29979464</ArticleId></ArticleIdList></Reference><Reference><Citation>McGoldrick P, Joyce PI, Fisher EM, et al. Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta 2013;1832:1421&#x2013;36</Citation><ArticleIdList><ArticleId IdType="pubmed">23524377</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Rothstein JD.. Rodent models of amyotrophic lateral sclerosis. Curr Protocols Pharmacol 2015;69:671&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ.. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;17:17&#x2013;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley WG, Andrew AS, Traynor BJ, et al. Gene-environment-time interactions in neurodegenerative diseases: Hypotheses and research approaches. Ann Neurosci 2018;25:261&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6470336</ArticleId><ArticleId IdType="pubmed">31000966</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K. Familial amyotrophic lateral sclerosis. Neurol Clin 2015;33:807&#x2013;30</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4670044</ArticleId><ArticleId IdType="pubmed">26515623</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20&#x2013;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyanagi K, Makifuchi T, Ohtoh T, et al. Amyotrophic lateral sclerosis of Guam: The nature of the neuropathological findings. Acta Neuropathol 1994;88:405&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">7847068</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting MG. Toxicity of cycads. Econ Bot 1963;17:270&#x2013;302</Citation></Reference><Reference><Citation>Kurland LT. An appraisal of the neurotoxicity of cycad and the etiology of amyotrophic lateral sclerosis on Guam. Fed Proc 1972;31:1540&#x2013;2</Citation><ArticleIdList><ArticleId IdType="pubmed">4561643</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley WG, Mash DC.. Beyond Guam: The cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases. Amyotroph Lateral Scler 2009;10: 7&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pubmed">19929726</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox PA, Banack SA, Murch SJ.. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci U S A 2003;100:13380&#x2013;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC263822</ArticleId><ArticleId IdType="pubmed">14612559</ArticleId></ArticleIdList></Reference><Reference><Citation>Banack SA, Murch SJ, Cox PA.. Neurotoxic flying foxes as dietary items for the Chamorro people, Marianas Islands. J Ethnopharmacol 2006;106:97&#x2013;104</Citation><ArticleIdList><ArticleId IdType="pubmed">16457975</ArticleId></ArticleIdList></Reference><Reference><Citation>Banack SA, Cox PA.. Creating a Simian Model of Guam ALS/PDC which reflects Chamorro lifetime BMAA exposures. Neurotox Res 2018;33:24&#x2013;32</Citation><ArticleIdList><ArticleId IdType="pubmed">28478528</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox PA, Davis DA, Mash DC, et al. Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain. Proc Biol Sci 2016;283:2015239</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4795023</ArticleId><ArticleId IdType="pubmed">26791617</ArticleId></ArticleIdList></Reference><Reference><Citation>Banack SA, Johnson HE, Cheng R, et al. Production of the neurotoxin BMAA by a marine cyanobacterium. Mar Drugs 2007;5:180&#x2013;96</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2365698</ArticleId><ArticleId IdType="pubmed">18463731</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox PA, Banack SA, Murch SJ, et al. Diverse taxa of cyanobacteria produce beta-N-methylamino-l-alanine, a neurotoxic amino acid. Proc Natl Acad Sci U S A 2005;102:5074&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC555964</ArticleId><ArticleId IdType="pubmed">15809446</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand LE, Pablo J, Compton A, et al. Cyanobacterial blooms and the occurrence of the neurotoxin beta-N-methylamino-l-alanine (BMAA) in South Florida aquatic food webs. Harmful Algae 2010;9:620&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2968748</ArticleId><ArticleId IdType="pubmed">21057660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondo K, Broc Glover W, Murch SJ, et al. Environmental neurotoxins beta-N-methylamino-l-alanine (BMAA) and mercury in shark cartilage dietary supplements. Food Chem Toxicol 2014;70:26&#x2013;32</Citation><ArticleIdList><ArticleId IdType="pubmed">24755394</ArticleId></ArticleIdList></Reference><Reference><Citation>Banack SA, Metcalf JS, Bradley WG, et al. Detection of cyanobacterial neurotoxin &#x3b2;-N-methylamino-l-alanine within shellfish in the diet of an ALS patient in Florida. Toxicon 2014;90:167&#x2013;73</Citation><ArticleIdList><ArticleId IdType="pubmed">25123936</ArticleId></ArticleIdList></Reference><Reference><Citation>Caller TA, Doolin JW, Haney JF, et al. A cluster of amyotrophic lateral sclerosis in New Hampshire: A possible role for toxic cyanobacteria blooms. Amyotroph Lateral Scler 2009;10(Suppl 2):101&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">19929741</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X, Basile M, Mash DC.. Cerebral uptake and protein incorporation of cyanobacterial toxin beta-N-methylamino-l-alanine. Neuroreport 2013;24:779&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pubmed">23979257</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan VX, Mazzocco C, Varney B, et al. Detection of the cyanotoxins l-BMAA uptake and accumulation in primary neurons and astrocytes. Neurotox Res 2018;33:55&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pubmed">28852990</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao SD, Banack SA, Cox PA, et al. BMAA selectively injures motor neurons via AMPA/kainate receptor activation. Exp Neurol 2006;201:244&#x2013;52</Citation><ArticleIdList><ArticleId IdType="pubmed">16764863</ArticleId></ArticleIdList></Reference><Reference><Citation>Albano R, Lobner D.. Transport of BMAA into neurons and astrocytes by system xc. Neurotox Res 2018;33:1&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pubmed">28470569</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobner D, Piana PM, Salous AK, et al. Beta-N-methylamino-l-alanine enhances neurotoxicity through multiple mechanisms. Neurobiol Dis 2007;25:360&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959771</ArticleId><ArticleId IdType="pubmed">17098435</ArticleId></ArticleIdList></Reference><Reference><Citation>Arif M, Kazim SF, Grundke-Iqbal I, et al. Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam. Proc Natl Acad Sci U S A 2014;111:1144&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903234</ArticleId><ArticleId IdType="pubmed">24395787</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu AS, Gehringer MM, Braidy N, et al. Gliotoxicity of the cyanotoxin, beta-methyl-amino-l-alanine (BMAA). Sci Rep 2013;3:1482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3601369</ArticleId><ArticleId IdType="pubmed">23508043</ArticleId></ArticleIdList></Reference><Reference><Citation>Beri J, Nash T, Martin RM, et al. Exposure to BMAA mirrors molecular processes linked to neurodegenerative disease. Proteomics 2017;17:1700161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828681</ArticleId><ArticleId IdType="pubmed">28837265</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor EA, Mowrey DD, Dokholyan NV. &#x3b2;-Methylamino-L-alanine substitution of serine in SOD1 suggests a direct role in ALS etiology. PLoS Comput Biol 2019;15:e1007225</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6668853</ArticleId><ArticleId IdType="pubmed">31323035</ArticleId></ArticleIdList></Reference><Reference><Citation>Glover WB, Baker Tc, Murch SJ, et al. Determination of beta-N-methylamino-l-alanine, N-(2-aminoethyl)glycine, and 2,4-diaminobutyric acid in food products containing cyanobacteria by ultra-performance liquid chromatography and tandem mass spectrometry: Single-laboratory validation. J AOAC Int 2015;98:1559&#x2013;65</Citation><ArticleIdList><ArticleId IdType="pubmed">26651568</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food. and Drug Administration, Center for Drug Evaluation and Research. Reviewer Guidance: Validation of Chromatographic Methods Washington, DC: Center for Drug Evaluation and Research 1994</Citation></Reference><Reference><Citation>Murch SJ, Cox PA, Banack SA, et al. Occurrence of beta-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand 2004;110:267&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">15355492</ArticleId></ArticleIdList></Reference><Reference><Citation>Pablo J, Banack SA, Cox PA, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer&#x2019;s disease. Acta Neurol Scand 2009;120:216&#x2013;25</Citation><ArticleIdList><ArticleId IdType="pubmed">19254284</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto K, Mizuno Y, Fujita Y.. Bunina bodies in amyotrophic lateral sclerosis. Neuropathology 2008;28:109&#x2013;15</Citation><ArticleIdList><ArticleId IdType="pubmed">18069968</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, Treleaven CM, Fidler JA, et al. Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis. Proc Natl Acad Sci U S A 2013;110:10812&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696768</ArticleId><ArticleId IdType="pubmed">23754387</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Geser F, Stieber A, et al. TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol 2013;125:121&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536927</ArticleId><ArticleId IdType="pubmed">23124365</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Kesavapany S, Pant HC.. The pathobiology of amyotrophic lateral sclerosis: A proteinopathy? J Neuropathol Exp Neurol 2005;64:649&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pubmed">16106213</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, Tanji K, Zhang HX, et al. Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol 2008;116:193&#x2013;203</Citation><ArticleIdList><ArticleId IdType="pubmed">18560845</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Winton MJ, Kwong LK, et al. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 2007;115:133&#x2013;45</Citation><ArticleIdList><ArticleId IdType="pubmed">17713769</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R, Neumann M.. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010;9:995&#x2013;1007</Citation><ArticleIdList><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Maekawa S, Leigh PN, King A, et al. TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations. Neuropathology 2009;29:672&#x2013;83</Citation><ArticleIdList><ArticleId IdType="pubmed">19496940</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin HZ, Yu S, Hsu CI, et al. Intrathecal infusion of BMAA induces selective motor neuron damage and astrogliosis in the ventral horn of the spinal cord. Exp Neurol 2014;261:1&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4194249</ArticleId><ArticleId IdType="pubmed">24918341</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Mello F, Braidy N, Marcal H, et al. Cytotoxic effects of environmental toxins on human glial cells. Neurotox Res 2017;31:245&#x2013;58</Citation><ArticleIdList><ArticleId IdType="pubmed">27796937</ArticleId></ArticleIdList></Reference><Reference><Citation>Geloso MC, Corvino V, Marchese E, et al. The dual role of microglia in ALS: Mechanisms and therapeutic approaches. Front Aging Neurosci 2017;9:242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5524666</ArticleId><ArticleId IdType="pubmed">28790913</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Metz I, Amor S, et al. Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons. Acta Neuropathol 2013;125:595&#x2013;608</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3611040</ArticleId><ArticleId IdType="pubmed">23354834</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox PA, Davis DA, Mash DC, et al. Do vervets and macaques respond differently to BMAA? Neurotoxicology 2016;57:310&#x2013;1</Citation><ArticleIdList><ArticleId IdType="pubmed">27133441</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda T. Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Neuropathology 2018;38:72&#x2013;81</Citation><ArticleIdList><ArticleId IdType="pubmed">28960544</ArticleId></ArticleIdList></Reference><Reference><Citation>Fainman J, Eid MD, Ervin FR, et al. A primate model for Alzheimer&#x2019;s disease: Investigation of the apolipoprotein E profile of the vervet monkey of St. Kitts. Am J Med Genet B Genet 2007;144B: 818&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">17373728</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyanagi K, Wada M.. Neuropathology of parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam: An update. J Neurol 1999;246(Suppl 2):II19&#x2013;27</Citation><ArticleIdList><ArticleId IdType="pubmed">10525999</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunlop RA, Cox PA, Banack SA, et al. The non-protein amino acid BMAA is misincorporated into human proteins in place of l-serine causing protein misfolding and aggregation. PLoS One 2013;8:e75376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3783393</ArticleId><ArticleId IdType="pubmed">24086518</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunlop RA, Powell JT, Metcalf JS, et al. l-Serine-mediated neuroprotection includes the upregulation of the ER stress chaperone protein disulfide isomerase (PDI). Neurotox Res 2018;33:113&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pubmed">28975502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Ding L, Gao C, et al. Neuroprotective effect of l-serine against white matter demyelination by harnessing and modulating inflammation in mice. Neuropharmacology 2019;146:39&#x2013;49</Citation><ArticleIdList><ArticleId IdType="pubmed">30452956</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltran-Castillo S, Eugenin J, von Bernhardi R.. Impact of aging in microglia-mediated d-serine balance in the CNS. Mediators Inflamm 2018;2018:7219732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6180939</ArticleId><ArticleId IdType="pubmed">30363571</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels BA, Wood L, Tremblay F, et al. Functional evidence for d-serine inhibition of non-N-methyl-d-aspartate ionotropic glutamate receptors in retinal neurons. Eur J Neurosci 2012;35:56&#x2013;65</Citation><ArticleIdList><ArticleId IdType="pubmed">22128843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolosker H, Balu DT, Coyle JT.. The rise and fall of the d-serine-mediated gliotransmission hypothesis. Trends Neurosci 2016;39:712&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5113294</ArticleId><ArticleId IdType="pubmed">27742076</ArticleId></ArticleIdList></Reference><Reference><Citation>Metcalf JS, Dunlop RA, Powell JT, et al. l-Serine: A naturally-occurring amino acid with therapeutic potential. Neurotox Res 2018;33:213&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pubmed">28929385</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TD, Miller RG, Bradley WG, et al. Phase I clinical trial of safety of l-serine for ALS patients. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:107&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pubmed">27589995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai PP, Xu LH, Yang JJ, et al. Reduction of inflammatory responses by l-serine treatment leads to neuroprotection in mice after traumatic brain injury. Neuropharmacology 2015;95:1&#x2013;11</Citation><ArticleIdList><ArticleId IdType="pubmed">25747604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren TJ, Qiang R, Jiang ZL, et al. Improvement in regional CBF by l-serine contributes to its neuroprotective effect in rats after focal cerebral ischemia. PLoS One 2013;8:e67044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692549</ArticleId><ArticleId IdType="pubmed">23825613</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>